A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

Phase 2 Completed 25 enrolled Incyte Corporation

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of parsaclisib administered orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin and evidence of ongoing hemolysis that requires treatment intervention.

Timeline

Start: 2018-11-21
Primary completion: 2021-08-05
Completion: 2024-04-02

Publications

Barcellini W, Pane F, Patriarca A, Murakhovskaya I, Terriou L, DeSancho MT, Hanna WT, Leopold L, Rappold E, Szeto K, Wei S, Jager U. Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study. Am J Hematol. 2024 Dec;99(12):2313-2320. doi: 10.1002/ajh.27493. Epub 2024 Oct 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Parsaclisib	Small molecule	1 mg	Oral
Subject	Parsaclisib	Small molecule	2.5 mg	Oral

A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

Summary

Timeline

Publications

Drugs

Indications